AN2 Therapeutics Inc

** The following materials are formatted in Inline XBRL (Extensible Business Reporting Language): (i) the cover page; (ii) the Condensed Balance Sheets as of March 31, 2024 and December 31, 2023; (iii) the Condensed Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023; (iv) the Condensed Statements of Stockholders' Equity for the three months ended March 31, 2024 and 2023; (vi) the Condensed Statements of Cash Flows for the three months ended March 31, 2024 and 2023; (vii) Notes to Condensed Financial Statements tagged as blocks of text.

† The certification attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.